INHIBITORY EFFECTS OF HISTAMINE H1-RECEPTOR BLOCKING-DRUGS ON METABOLIC ACTIVATIONS OF NEUTROPHILS

被引:17
作者
TANIGUCHI, K
MASUDA, Y
TAKANAKA, K
机构
[1] Department of Toxicology, Niigata College of Pharmacy, Niigata, 5-13-2 Kamishineicho
来源
JOURNAL OF PHARMACOBIO-DYNAMICS | 1991年 / 14卷 / 02期
关键词
NEUTROPHIL; METABOLIC RESPONSE; HISTAMINE RECEPTOR BLOCKING DRUG; ARACHIDONIC ACID; LEUKOTRIENE;
D O I
10.1248/bpb1978.14.87
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Inhibitory effects of various histamine receptor-blocking agents including antiallergic agents on metabolic activations of neutrophils were examined by measuring leukotrienes (C4, D4 and E4) formation, arachidonic acid release and superoxide generation. The stimulation of neutrophils by calcium ionophore (A23187) causes the production of leukotrienes concomitantly with the release of arachidonic acid from the cells and these were effectively diminished with a variety of antihistaminic agents. Almost all the histamine H-1 receptor-blocking drugs studied here showed as inhibitors of the metabolic activations of neutrophils, although the degree was dependent on the drug concentrations. The order of potency of the inhibitory effects on the arachidonic acid release were: homochlorcyclizine, clemastine, and azelastine (IC50 < 20-mu-M) > oxatomide (IC50 < 60-mu-M) and diphenylpyraline > triprolidine, meclizine, diphenhydramine (IC50 > 100-mu-M). The superoxide generation from neutrophils activated by phorbol 12-myristate 13-acetate was also effectively inhibited by these agents, but generally lower concentrations were required to obtain the same degrees of effects. These results indicated that some of the histamine H-1 receptor-blocking drugs, such as clemastine and homochlorcyclizine, may act as inhibitors of formation of leukotrienes at the locus of inflammation.
引用
收藏
页码:87 / 93
页数:7
相关论文
共 30 条
[1]   HISTAMINE-RELEASE INHIBITION AND PREVENTION OF THE DECREASE IN MEMBRANE FLUIDITY INDUCED BY CERTAIN ANTI-ALLERGIC DRUGS - ANALYSIS OF THE INHIBITORY MECHANISM OF NCO-650 [J].
AKAGI, M ;
MIO, M ;
TASAKA, K .
AGENTS AND ACTIONS, 1983, 13 (2-3) :149-156
[2]  
BAINTON DF, 1980, CELL BIOL INFLAMMATI, P18
[3]  
BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911
[4]   ANTIALLERGIC ACTIVITY OF H1-RECEPTOR ANTAGONISTS ASSESSED BY NASAL CHALLENGE [J].
BOUSQUET, J ;
LEBEL, B ;
CHANAL, I ;
MOREL, A ;
MICHEL, FB .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1988, 82 (05) :881-887
[5]  
BUSSE W, 1988, J ALLERGY CLIN IMMUN, V82, P890, DOI 10.1016/0091-6749(88)90031-0
[6]   LORATADINE - A PRELIMINARY REVIEW OF ITS PHARMACODYNAMIC PROPERTIES AND THERAPEUTIC EFFICACY [J].
CLISSOLD, SP ;
SORKIN, EM ;
GOA, KL .
DRUGS, 1989, 37 (01) :42-57
[7]   LEUKOTRIENES ARE POTENT CONSTRICTORS OF HUMAN BRONCHI [J].
DAHLEN, SE ;
HEDQVIST, P ;
HAMMARSTROM, S ;
SAMUELSSON, B .
NATURE, 1980, 288 (5790) :484-486
[8]   ALLERGEN CHALLENGE OF LUNG-TISSUE FROM ASTHMATICS ELICITS BRONCHIAL CONTRACTION THAT CORRELATES WITH THE RELEASE OF LEUKOTRIENE-C4, LEUKOTRIENE-D4, AND LEUKOTRIENE-E4 [J].
DAHLEN, SE ;
HANSSON, G ;
HEDQVIST, P ;
BJORCK, T ;
GRANSTROM, E ;
DAHLEN, B .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1983, 80 (06) :1712-1716
[9]   COMPARATIVE AIRWAY AND VASCULAR ACTIVITIES OF LEUKOTRIENE-C-1 AND LEUKOTRIENE-D INVIVO AND INVITRO [J].
DRAZEN, JM ;
AUSTEN, KF ;
LEWIS, RA ;
CLARK, DA ;
GOTO, G ;
MARFAT, A ;
COREY, EJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1980, 77 (07) :4354-4358
[10]   LEUKOTRIENE-B, A POTENT CHEMOKINETIC AND AGGREGATING SUBSTANCE RELEASED FROM POLYMORPHONUCLEAR LEUKOCYTES [J].
FORDHUTCHINSON, AW ;
BRAY, MA ;
DOIG, MV ;
SHIPLEY, ME ;
SMITH, MJH .
NATURE, 1980, 286 (5770) :264-265